Their study showed that paeoniflorin elevated plasma HDL-cholesterol levels and decreased plasma concentrations of LDL-cholesterol, total cholesterol, triglycerides, malondialdehyde, and 8-isoprostane by downregulating the expression of ANGPTL3 and upregulating the expression of GALT2 and LPL, alleviating dyslipidemia in mice. This evidence concerns the gene LPL and metabolic syndrome.